UiPath plunges after Q4 results, but Needham upgrades to Buy on new ARR

UiPath (PATH) stock slides after Q4 FY26 results as Needham upgrades to Buy on ARR and free cash flow growth; AI ARR hits $200M.
Insider Monkey

UiPath, Inc (PATH) Launches New AI Tools for Healthcare

UiPath, Inc. (NYSE:PATH) is one of the Best All-Time Low Stocks to Invest In Now. On February 23, UiPath, Inc. (NYSE:PATH), which is a leader in robotic process automation, launched new AI tools, ...
The Motley Fool

This Could Be One of the Most Important Stocks in Tech By 2028

UiPath is looking to become an AI agent orchestration platform. The company's roots in RPA give it a strong foundation to become a leading agentic AI orchestration platform. The stock is very cheap at ...
Seeking Alpha

Forget The Current Software Fears: UiPath Combines Software With AI And It Works

UiPath Inc. is rated a strong buy, with a price target near $18, following a 30% sell-off driven by AI-related sector fears. PATH's robust AI-driven automation platform, strong earnings beats, and 16% ...